Alnylam Pharmaceuticals, Inc. reported $3.71B of revenue over the trailing twelve months, +65% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $3.71B (to Q4 2025). Net income: $272M, trailing twelve months to Q4 2025. Free cash flow: $465M, trailing twelve months to Q4 2025. Operating margin: 11%, trailing twelve months to Q4 2025.

ALNYAlnylam Pharmaceuticals, Inc.

Healthcare

$232.57-49% 1Y

$232.57

$216.4652 weeks$491.22

ALNY as reported

Alnylam Pharmaceuticals, Inc. reported $3.71B of revenue over the trailing twelve months, +65% on the year before. 10 reported series are charted on this page, each one as filed.

$3.71B

Revenue, trailing twelve months · to Q4 2025 · +65% against the twelve months before

Net income: $272M
Net income · −198% year on year · trailing twelve months to Q4 2025
Free cash flow: $465M
Free cash flow · −1193% year on year · trailing twelve months to Q4 2025
Operating margin: 11%
Operating margin · trailing twelve months to Q4 2025

Details›

Every series Ryufin has for ALNY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$3.71B	+65%	Q4 2025
Net income	$272M	−198%	Q4 2025
EPS	$1.97	−191%	Q4 2025
Gross margin	82%	n/a	Q4 2025
Operating margin	11%	n/a	Q4 2025
Net margin	4.5%	n/a	Q4 2025
ROE	−9.6%	n/a	Q4 2025
ROA	−1.2%	n/a	Q4 2025
ROIC	49%	n/a	Q2 2022 · 14 quarters behind
Free cash flow	$465M	−1193%	Q4 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.